mRNA

Moderna has reported encouraging interim data from its Phase I/II trial of mRNA-3927, an mRNA therapy for rare metabolic disorder propionic acidemia (PA). The data was presented at the 2023 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting. The ongoing global Phase I/II clinical trial is a multicentre, open-label study designed to assess […]

A clinical trial of an experimental universal influenza vaccine developed by researchers at the National Institute of Allergy and Infectious Diseases’ (NIAID) Vaccine Research Center (VRC) has begun enrolling volunteers at Duke University in Durham, North Carolina. This Phase I trial will test the experimental vaccine, known as H1ssF-3928 mRNA-LNP, for safety and its ability […]

This is the latest episode of the free DDW narrated podcast, “The impact of technology on drug discovery”. It covers two articles written for Volume 23, Issue 2 – Spring 2022 of DDW. They are called “Talking Tech” and “Rejuvenation biotech: Can this company make age a thing of the past?” With Covid-19 taking so […]

DDW’s Megan Thomas rounds up highlights from Sunday 16 April at AACR 2023, from promising trial results for a personalised mRNA-based cancer vaccine to winners of lifetime achievement awards. Opening plenary session Sunday’s opening plenary session borrowed its name from the Annual Meeting theme, “Advancing the Frontiers of Cancer Science and Medicine”, which kicked off […]

Personalised mRNA-based cancer vaccine mRNA-4157/V940, in combination with the immune checkpoint inhibitor pembrolizumab (Keytruda) improved recurrence-free survival (RFS) compared with pembrolizumab alone in patients with high-risk melanoma. The clinical benefit was observed regardless of the tumour mutational burden (TMB) status, according to results from the Phase IIb KEYNOTE-942 clinical trial presented at the AACR Annual Meeting […]

In an exclusive interview with The Guardian, Moderna said that cancer and heart disease vaccines would be ready by 20301. The pharmaceutical firm also provided promising updates on mRNA-4157/V940, which targets different tumour types, at Moderna’s Vaccines Day on 24 March 20232.   The first detailed results of the trial will be presented at the American […]

A new eBook is now available entitled ‘Riding the mRNA highway: development, manufacturing, and beyond’, sponsored by Thermo Fisher Scientific. Download the eBook to learn more about process development and manufacturing in the mRNA space to enable successful scale-ups of mRNA production for therapeutic applications. Topics covered in the eBook include: Expert views on mRNA […]

Download this eBook to learn more about process development and manufacturing in the mRNA space to enable successful scale-ups of mRNA production for therapeutic applications. Topics covered in the eBook include: Expert views on mRNA development and manufacturing Advantages of mRNA processes compared to traditional vaccine manufacturing Best practices for scale up of in vitro […]

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  In the news this week, we have covered a number of early-stage studies that could lead to potentially huge breakthroughs in the treatment […]

News round-up for 13-17 March by DDW Digital Content Editor Diana Spencer.  In the news this week we have covered a number of early-stage studies that could lead to potentially huge breakthroughs in the treatment of metastatic breast cancer, long Covid, bacterial diseases, bone cancer, and autoimmune conditions.   The top stories:  mRNA vaccine 100% effective […]